Pharma companies had success increasing med use by sending reps to meet with docs to provide interactive educational sessions. Can that educational model be harnessed for good? Yes! Read our systematic review on Academic Detailing led by @bnrome pubmed.ncbi.nlm.nih.gov/3977…

🚨New paper in @AnnalsofIM about everybody's favorite medication to hate🚨 Gabapentin is far from the perfect pain med, but the risk/benefit profile may be more complex than papers comparing users to non-users could have you believe Tweetorial en route! pubmed.ncbi.nlm.nih.gov/3976…

This is the type of education everybody, but especially pre-meds + medical students, should be getting. Journal clubs are great and can teach some about biased study designs and reporting, but there are so many more lessons for most clinicians here. #Medtwitter #MedEd

Loved what this paper set out to do, but unfortunately my reading is there still isn't good evidence to deprescribe antihypertensive medications in older adults. Come learn why 👇 #Medtwitter #Cardiotwitter

Ok most people feel 2nd author is distinct from other middle authors. Follow-up for #Medtwitter / #Epitwitter health services/clinical researchers: What is reasonable to expect from non-2nd middle authors (assume original articles being submitted to clinical journals)?

For older adults, starting a new cardioprotective medicine is not equivalent to having to continue an old one. Whether you're interested in prescribing or deprescribing, our randomized experiment has something for you 👇#cardiotwitter #medtwitter pubmed.ncbi.nlm.nih.gov/3956…

Hey #MedTwitter #Epitwitter and whoever else does health services/clinical research, curious your thoughts about author contributions. Question 1: Assuming >3 authors on a paper, does second author carry any extra weight over being another middle author?

Reminder that binary thinking about medications is not patient-centered. Less strong opinions about medicines being "good" or "bad." More opinions on the right medicine for the right patient at the right time. #medtwitter

We need an index that describes how often your paper is cited vs how often it is read. Said index for "Crossing the Quality Chasm" would be enormous. If you had to prove you read a paper before citing it, 92% of the background sections in the medical literature would be gone.

Is there a service that offers patients a doctor/nurse to accompany them during outpatient visits? Like pay a small fee get an expert to help+make sure you're heard? The care my family gets for even simple concerns when I'm there vs when I'm not is staggeringly different.

Cool idea in general, but still waiting for a trial proving that stopping meds folks are tolerating improves outcomes. We should stop meds that don't offer benefit regardless, but the speed/lengths we go to should depend on magnitude of risk reduction offered by deprescribing.

I love working with friends. Some of that is selfishness. Some of it is that friends have given me some of the best feedback on ideas. I recommend the lack of hierarchy, honesty, kind skepticism, unbridled enthusiasm, and more that working with friends brings. #medtwitter

New review w/ @AlexanderZheut1 - Epidemiology of Hypertension in Older Adults Are you looking for historical context? Disease and treatment prevalence estimates? Psychological and cost implications? Well then have we got an article for you #medtwitter👇 pubmed.ncbi.nlm.nih.gov/3934…

Why risk-based prescribing for some things and not others. Why are surrogates endpoints ok for some things that reduce cardiovascular risk but not others? New drugs means lots of new areas to think about.